Open AccessComparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
Author(s) -
Taro Kishi,
Kazuto Oya,
Yoshihiko Matsui,
Ikuo Nomura,
Kenji Sakuma,
Makoto Okuya,
Yuki Matsuda,
Kiyoshi Fujita,
Toshihiko Funahashi,
Reiji Yoshimura,
Nakao Iwata
Publication year - 2018
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s176676
Subject(s) - positive and negative syndrome scale , medicine , placebo , discontinuation , adverse effect , randomized controlled trial , meta analysis , schizophrenia (object oriented programming) , tolerability , clinical global impression , psychiatry , psychosis , pathology , alternative medicine
The purpose of this study was to compare the efficacy and safety of brexpiprazole 4 mg/day (B4) and 2 mg/day (B2) for treating acute schizophrenia.